• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

A Glycolipid Adjuvant, 7DW8-5, Enhances the Protective Immune Response to the Current Split Influenza Vaccine in Mice

tetano

Editor, Senior Moderator
Front Microbiol. 2019 Sep 18;10:2157. doi: 10.3389/fmicb.2019.02157. eCollection 2019. [h=1]A Glycolipid Adjuvant, 7DW8-5, Enhances the Protective Immune Response to the Current Split Influenza Vaccine in Mice.[/h]
Feng H[SUP]1[/SUP], Nakajima N[SUP]2[/SUP], Wu L[SUP]1[/SUP], Yamashita M[SUP]1[/SUP], Lopes TJS[SUP]3[/SUP], Tsuji M[SUP]4[/SUP], Hasegawa H[SUP]2[/SUP], Watanabe T[SUP]1[/SUP], Kawaoka Y[SUP]1,[/SUP][SUP]3,[/SUP][SUP]5[/SUP].
[h=3]Author information[/h] 1 Division of Virology, Department of Microbiology and Immunology, The Institute of Medical Science, University of Tokyo, Tokyo, Japan. 2 Department of Pathology, The National Institute of Infectious Diseases, Tokyo, Japan. 3 Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, United States. 4 Aaron Diamond AIDS Research Center, Affiliate of the Rockefeller University, New York, NY, United States. 5 Department of Special Pathogens, International Research Center for Infectious Diseases, Institute of Medical Science, University of Tokyo, Tokyo, Japan.

[h=3]Abstract[/h] Vaccination is an effective strategy to control influenza disease. Adjuvants enhance the efficacy of vaccines, but few adjuvants are approved for human use, so novel, safe, and effective adjuvants are urgently needed. The glycolipid adjuvant 7DW8-5 has shown adjuvanticity to malaria vaccine; however, its adjuvant effect for seasonal influenza vaccine remains unknown. Here, we evaluated the adjuvanticity of 7DW8-5 to a quadrivalent split influenza vaccine in a mouse model. 7DW8-5 significantly enhanced virus-specific antibody production when administrated with influenza vaccine compared with that of vaccine alone; 10 μg of 7DW8-5 induced similar antibody levels to those induced by alum. Mouse body weight loss was reduced and, notably, the survival rate was increased in the vaccine plus 7DW8-5 group compared with that in the vaccine plus alum group. Our results indicate that the glycolipid 7DW8-5 is a promising adjuvant for influenza vaccine.
Copyright ? 2019 Feng, Nakajima, Wu, Yamashita, Lopes, Tsuji, Hasegawa, Watanabe and Kawaoka.


[h=4]KEYWORDS:[/h] 7DW8-5; adjuvants; glycolipid; influenza vaccine; mice

PMID: 31620111 PMCID: PMC6759631 DOI: 10.3389/fmicb.2019.02157
Free full text
 
Back
Top Bottom